Uridine Suppresses Osteoclast Differentiation and Mitigates Osteoporosis via PI3K/Akt–FoxO
Overview
This study identifies uridine (UD) as a critical metabolite that declines during osteoclast differentiation and demonstrates that UD supplementation suppresses osteoclast development and bone resorption. UD mitigates osteoporosis in ovariectomized mice by modulating the PI3K/Akt–FoxO signaling pathway, reducing reactive oxygen species (ROS) accumulation and inhibiting NFATc1 activation.
Background
Osteoporosis is characterized by excessive osteoclast activity leading to bone loss and increased fracture risk, especially in postmenopausal women due to estrogen deficiency. Osteoclast differentiation is driven by RANKL signaling and enhanced by ROS accumulation, which is regulated by the PI3K/Akt–FoxO pathway. While glucose and lipid metabolism have been studied in osteoclastogenesis, the role of pyrimidine metabolism, particularly uridine, remains unclear. Uridine has known antioxidant properties and may influence bone metabolism through redox regulation.
Data Highlights
Parameter
Effect of Uridine (UD)
Osteoclast differentiation
Significantly suppressed in vitro (RAW264.7 cells, BMMs)
Expression of NFATc1 and CTSK
Reduced with UD treatment
Trabecular microarchitecture in OVX mice
Improved after UD administration
Osteoclast burden in OVX mice
Reduced with UD treatment
PI3K/Akt phosphorylation
Inhibited by UD
FoxO nuclear translocation
Facilitated by UD
ROS accumulation
Suppressed by UD
Key Findings
Uridine levels significantly decline during RANKL-induced osteoclast differentiation.
Exogenous uridine supplementation suppresses osteoclast development and resorptive function in vitro.
Uridine reduces expression of osteoclast-specific markers NFATc1 and cathepsin K.
In ovariectomized mice, uridine improves bone microarchitecture and reduces osteoclast numbers, mitigating bone loss.
Uridine supplementation represents a promising therapeutic strategy to inhibit osteoclast-mediated bone resorption by restoring redox balance via the PI3K/Akt–FoxO pathway. This approach may offer a safer alternative or adjunct to current osteoporosis treatments, potentially reducing adverse effects and improving long-term bone health.
Conclusion
This study reveals a novel metabolic-signaling mechanism linking pyrimidine metabolism to osteoclast differentiation and establishes uridine as a potential metabolic regulator for osteoporosis prevention and treatment.
References
Original Study -- Uridine Suppresses ROS-Driven Osteoclast Differentiation and Mitigates Osteoporosis
